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Why are HIV-positive individuals still dying of tuberculosis?
Tuberculosis and HIV have been seen as intertwined 
since the earliest report of AIDS more than 30 years 
ago.1 Despite the remarkable success of the expansion 
of access to antiretroviral therapy, deaths due to HIV-
related tuberculosis remain common. WHO estimated 
the number of such deaths to be 0·4 million in 2014.2 
This number is not straightforward to estimate. The 
more clinicians test for tuberculosis in patients with 
advanced HIV, the more patients with tuberculosis they 
find.3 Yet the introduction of more sensitive diagnostic 
tools has not reduced mortality.4 For years pathologists 
have highlighted that many patients dying with HIV 
infection do so either from or with tuberculosis, and 
that the diagnosis of tuberculosis had often not been 
made ante-mortem.5,6 Epidemiologists show that in 
adults found in random population samples from 
Africa and Asia with respiratory samples from which 
Mycobacterium tuberculosis can be cultured, a substantial 
proportion deny having any symptoms that would 
make a clinician consider a diagnosis of tuberculosis.7,8 
Pragmatists have therefore proposed that to reduce 
mortality, we should consider giving patients with 
advanced HIV infection empirical treatment for 
tuberculosis regardless of whether or not such a 
diagnosis can be confirmed.9
The REMEMBER study team report the first of three 
large randomised trials10 to address the question of 
whether such empirical treatment can reduce mortality 
in those with advanced HIV infection. 850 individuals 
with advanced HIV (CD4 cell counts of <50 cells/µL) 
were randomly assigned (1:1) to either the empirical 
group (antiretroviral therapy and empirical tuberculosis 
therapy; n=424) or the isoniazid preventive therapy 
group (antiretroviral therapy and isoniazid preventive 
therapy; n=426). Although the study did not suggest 
a difference in the primary endpoint (mortality or 
unknown vital status after 6 months) with 22 events 
in each group (absolute risk difference –0·06% [95% CI 
–3·05 to 2·94]) of which only two were of unknown vital 
status, both in the empirical group, the low event 
rate limits the power of the study. The exclusion of 
participants with suspected but not confirmed 
tuberculosis excludes one group of patients who would 
be expected to benefit from the empirical treatment 
strategy.
A somewhat surprising observation was that, 
even during the 6 month treatment period, incident 
tuberculosis was diagnosed more commonly in the 
empirical treatment group than in those given isoniazid 
alone. However, this study is an open-label trial without 
strong diagnostic criteria, and therefore this observation 
must not be overinterpreted. A possible explanation 
for this finding is that adherence to the empirical 
treatment was likely to be lower than to the isoniazid 
treatment because of the higher pill burden and greater 
toxicity of pyrazinamide. Any lack of adherence would 
have reduced the power to show a benefit of empirical 
treatment.
Nonetheless, as the authors point out, the study 
could not suggest any additional benefit of empirical 
treatment for tuberculosis in patients in whom 
thorough screening had been done. By contrast, the 
study suggests that isoniazid preventive therapy is safe 
and well tolerated, even in the context of advanced HIV 
infection. Other studies12 have also confirmed the clear 
benefit of isoniazid preventive therapy for HIV-positive 
individuals in Africa regardless of their CD4 cell count11 
and in addition to the benefits of antiretroviral therapy.12
A different and more pragmatic approach to 
empirical treatment was used in the TB Fast Track trial13 
presented at the 2016 Conference on Retroviruses and 
Opportunistic Infections. In this cluster-randomised 
trial, 24 primary care clinics in South Africa were 
randomly assigned to either a continued standard 
of care or to a nurse-led strategy that used a positive 
urine lateral flow assay for lipoaribinomannan, a 
haemoglobin concentration of less than 10 g/dL, or a 
body-mass index of less than 18·5 to categorise patients 
with HIV infection and less than 150 CD4 cells per mL 
into a high probability of tuberculosis group, in whom 
empirical treatment was started immediately, followed 
by antiretroviral therapy. Despite many more patients 
receiving empirical treatment in the fast track group 
of the study, no difference was reported in the primary 
endpoint of mortality (which was around twice as high 
as that found in the REMEMBER study). The authors of 
the TB Fast Track study noted that although patients 
in the intervention group started antituberculosis 
treatment quickly, a smaller proportion had started 
antiretroviral thearpy within 1 month of recruitment 
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than in the control group, possibly because of ongoing 
reluctance in primary care staff to initiate antiretroviral 
therapy in patients who had recently started 
antituberculosis treatment.
These large rigorous studies of empirical tuberculosis 
treatment did not support an effect on mortality 
in those with advanced HIV infection. Both studies 
highlight the ongoing tragedy of deaths associated 
with late presentation with advanced HIV disease. The 
solution is conceptually easy, has widespread political 
support, and has been advocated for many years, but 
clearly remains a challenge in many communities. We 
should remove the social, financial, and health and 
laboratory system barriers that prevent earlier diagnosis 
of HIV; we should offer antiretroviral therapy to all 
people with HIV long before their CD4 cell counts fall to 
the levels seen in the participants in these studies; and, 
as REMEMBER reminds us, we should screen all HIV-
positive individuals for tuberculosis, with the best tools 
that we have available and, where there is no strong 
suspicion of tuberculosis, we should offer individuals 
isoniazid preventive therapy.
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